UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 ...

Pioneering transformative medicines that target the endocannabinoid system RESOLVE-1 Phase 3 Study of Lenabasum in Systemic Sclerosis NASDAQ: CRBP @corbuspharma © 2019 Corbus Pharmaceuticals Holdings, Inc. | R&D Day June 21, 2019 www.corbuspharma.com © 2020 Corbus Pharmaceuticals Holdings, Inc. Systemic Sclerosis: The Unmet Need 2 © 2020 Corbus Pharmaceuticals Holdings, Inc. 09 Nov 2020 © 2019 Corbus Pharmaceuticals Holdings, Inc. | R&D Day June 21, 2019 Systemic sclerosis is a rare, debilitating and life-t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Ted Jenkins - Senior Director, IR and Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer and Head, Research Craig Millian - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies & Co. Leland Gershell - Oppenheimer & Company Dae Gon Ha - BTIG Elemer Piros - Roth Capi ...

CORBUS PHARMACEUTICALS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma ® | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 per share CRBP Nasdaq Global Market FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ________ ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Ted Jenkins - Senior Director, IR and Corporate Communications Yuval Cohen - CEO Barbara White - CMO and Head, Research Craig Millian - CCO Conference Call Participants Bert Kinsey - RBC Capital Markets Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Christopher Marai - Nomura Instinet Operator Good morning and welcome to the Corbus Pharmaceuticals Quarterly Update Confe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol Name of each exchange where registered Common Stock, par value $0.0001 per share CRBP The NASDAQ Global Market FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ________ TO ________. COMMI ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Ted Jenkins - Senior Director, Investor Relations and Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer and Head, Research Craig Millian - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Operator Good morning and welcome to the C ...

CORBUS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...